Company Oxford Biomedica plc

Equities

OXB

GB00BDFBVT43

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sales per Business

Sales per region

Ratings for Oxford Biomedica plc

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs

Market Closed - London S.E. Other stock markets 11:35:17 2024-04-19 am EDT			5-day change	1st Jan Change
203 ^GBX	-0.98%		+0.25%	-7.73%

Apr. 18	Stifel Upgrades Oxford BioMedica to Buy from Hold, Lifts PT	MT
Apr. 18	HSBC likes Haleon, cuts Flutter to 'hold'	AN

Oxford Biomedica plc is a United Kingdom-based cell and gene therapy research, development and bio-processing company. The Company is engaged in providing services to third parties, as well as performing internal research and development for its own purposes. It performs a range of analytical assays within its in-house quality check (QC) labs. The Company operates through two segments: Platform and Product. Platform segment is involved in bio-processing and processes development activities undertaken process by third parties, which is the partner programme for LentiVector and AAV CDMOs business. The segment also includes internal technology developments and technical intellectual property within the LentiVector platform. Product segment consists of the clinical and pre-clinical development of in vivo and ex vivo cell and gene therapy products (gene therapeutics), which are owned by the Company.

Number of employees: 891

GBP in Million	2021	Weight	2022	Weight	Delta
Platform 99.9 %	143	99.9 %	140	99.9 %	-1.96%
Product 0.1 %	0	0.1 %	0	0.1 %	-17.31%

GBP in Million	2021	Weight	2022	Weight	Delta
United States 44.0 %	-	-	62	44.0 %	-
United Kingdom 35.7 %	-	-	50	35.7 %	-
Europe 20.0 %	116	81.1 %	28	20.0 %	-75.76%
Rest of World 0.3 %	27	18.9 %	0	0.3 %	-98.54%

Managers	Title	Age	Since
Frank Mathias CEO	Chief Executive Officer	62	23-03-26
Stuart Paynter DFI	Director of Finance/CFO	52	17-08-28
Frederic Roch Doliveux CHM	Chairman	68	20-06-23
Nick Page COO	Chief Operating Officer	-	19-04-02
James Miskin CTO	Chief Tech/Sci/R&D Officer	-	99-12-31
Matthew Treagus CTO	Chief Tech/Sci/R&D Officer	-	21-07-31
Kyriacos Mitrophanous CTO	Chief Tech/Sci/R&D Officer	-	96-12-31
Sophia Bolhassan IRC	Investor Relations Contact	-	21-09-30
Natalie Walter IRO	Public Communications Contact	50	19-04-30
Lisa James HRO	Human Resources Officer	-	15-12-31

Members of the board	Title	Age	Since
Leone Patterson BRD	Director/Board Member	61	23-04-30
Frederic Roch Doliveux CHM	Chairman	68	20-06-23
Stuart Henderson BRD	Director/Board Member	66	16-05-31
Heather Elizabeth Preston BRD	Director/Board Member	58	18-03-14
Michael Hayden BRD	Director/Board Member	72	21-07-14
Dame Davies BRD	Director/Board Member	73	21-02-28
Catherine Moukheibir BRD	Director/Board Member	64	21-12-13
Stuart Paynter DFI	Director of Finance/CFO	52	17-08-28
Robert Ghenchev BRD	Director/Board Member	40	19-06-23
Namrata Patel BRD	Director/Board Member	-	22-04-12

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	100,000,296	80,810,643 ( 80.81 %)	0	80.81 %

Name	Equities	%	Valuation
Novo Nordisk Fonden 11.80 %	11,798,802	11.80 %	30 M p
Vulpes Investment Management Pte Ltd. 8.442 %	8,437,978	8.442 %	21 M p
Liontrust Investment Partners LLP 8.048 %	8,044,568	8.048 %	20 M p
Compagnie Merieux Alliance SAS 6.152 %	6,149,374	6.152 %	16 M p
M&G Investment Management Ltd. 5.070 %	5,067,751	5.070 %	13 M p
Global Alpha Capital Management Ltd. 3.883 %	3,880,863	3.883 %	10 M p
Nine Ten Partners LP 3.389 %	3,387,228	3.389 %	9 M p
Serum Institute Life Sciences Pvt Ltd. 3.384 %	3,382,950	3.384 %	9 M p
Hargreaves Lansdown Asset Management Ltd. 3.032 %	3,031,200	3.032 %	8 M p
Vitruvian Partners LLP 3.006 %	3,004,567	3.006 %	8 M p

Oxford Biomedica Plc

Windrush Court Transport Way

OX4 6LT, Oxford

+44 1865 783 000

http://www.oxfordbiomedica.co.uk

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

2.05 GBP

Average target price

3.963 GBP

Spread / Average Target

+93.33%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
OXFORD BIOMEDICA PLC	-6.82%	256M
VERTEX PHARMACEUTICALS INCORPORATED	-3.30%	102B
REGENERON PHARMACEUTICALS, INC.	+1.79%	96.07B
ARGENX SE	-0.44%	21.66B
BIONTECH SE	-18.35%	20.77B
GENMAB A/S	-7.45%	18.53B
WUXI APPTEC CO., LTD.	-40.31%	16.91B
BEIGENE, LTD.	-26.84%	13.79B
NEUROCRINE BIOSCIENCES, INC.	+0.59%	13.33B
SAREPTA THERAPEUTICS, INC.	+20.86%	10.94B

Bio Therapeutic Drugs